PACS

PACS Group, Inc.

PACS Group, Inc. (PACS) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (C). The rating has held at C+ for 9 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
C
Factor Score 2.3 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 27.3
EV / EBITDA 22.1
Rev Growth YoY 11.5%
Gross Margin 17.8%
Price Return 3M 9.0%
Price Return 12M 321.6%
Catalyst Signal 0.00
Market Cap $7.7B
TTM Revenue $5.7B
Price / Sales 1.3
ROE 26.5%

Historical Factor Score Progression

Held C+ for 9 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.8) C (2.3) B (3.3) B- (3.0) C+ (2.6) C+ (2.8)
2026-11-07 C+ (2.7) C (2.2) B (3.3) B- (3.0) C+ (2.7) C+ (2.8)
2026-10-31 C+ (2.8) C (2.3) B (3.2) B- (3.0) C+ (2.7) C+ (2.8)
2026-10-24 C+ (2.8) C (2.3) B (3.3) C+ (2.8) C+ (2.6) C+ (2.8)
2026-10-17 C+ (2.8) C (2.3) B (3.3) C+ (2.8) C+ (2.6) C+ (2.8)
Page 1 of 4